Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

.

As expected, Gen-Probe's total revenues and net income in the first quarter of 2008 benefited from $16.4 million of royalty and license revenue received from Bayer, representing the third and final payment due in connection with the 2006 settlement of the companies' patent infringement litigation.

Detailed Results

Gen-Probe's clinical diagnostics sales in the first quarter of 2008 benefited from continued growth of the APTIMA Combo 2(R) assay, an amplified nucleic acid test (NAT) for simultaneously detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). Sales of this assay increased based on market share gains on both the Company's semi-automated instrument platform and on the high-throughput, fully automated TIGRIS(R) system. Revenue from the PACE(R) product line, the Company's non-amplified tests for the same microorganisms, declined in the first quarter compared to the prior year period, in line with Gen-Probe's expectations.

In blood screening, product sales in the first quarter of 2008 benefited from continued international expansion of the PROCLEIX ULTRIO assay, from higher pricing associated with U.S. commercial sales of the PROCLEIX WNV (West Nile virus) assay on the TIGRIS system, from the timing of product shipments, and from increased sales of TIGRIS instruments to Chiron. The Company's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics.

Product sales were, in millions:

Three Months Ended March 31,

2008 2007 Change

Clinical diagnostics $52.5 $47.6 10 %

Blood screening $49.0 $39.6 24 %

Total product sales $101.5 $87.2 16 %

Collaborative research revenues for the first quarter of 2008 were $2.5 million, compared to $2.4
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Joshua Hare to Chair the Board LA JOLLA, Calif., ... CDXP) announced today the formation of a Medical Advisory ... program of CDP-1050 for the treatment of heart failure.The ... in the design and oversight of the planned CDP-1050 ...
... /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, Inc. (OTC ... the,Company,), one of the leading plasma-based ... China (,PRC,), today announced that the ... Products Co.,Ltd. (,Shandong Taibang,) has been ...
... Pain IndicationsLA JOLLA, Calif., Feb. 11 TorreyPines ... announced that oral administration of NGX426, an AMPA/kainate-type ... healthy male and female subjects when dosed once ... this Phase I trial demonstrating the safety and ...
Cached Biology Technology:Cordex Pharma Forms Heart Failure Medical Advisory Board 2Cordex Pharma Forms Heart Failure Medical Advisory Board 3Cordex Pharma Forms Heart Failure Medical Advisory Board 4Cordex Pharma Forms Heart Failure Medical Advisory Board 5China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... of light for more than a billion people in developing ... overlooked in greenhouse gas estimates, according to a new study ... the University of Illinois. Results from field and ... kerosene in wick lamps used for light in 250-300 ...
... varieties with higher yields and enhanced nutritional content, researchers ... with scientists at nine other institutions in an attempt ... endeavor, led by researchers at the U.K.-based Biotechnology and ... in the journal Nature . "This work ...
... white blood cells has a surprising second role in protecting ... researchers report. The molecule, microRNA-223, affects how cells respond to ... and thus the cells, likelihood of suffering permanent damage. ... very specific effects in the brain, one that could be ...
Cached Biology News:Study IDs kerosene lamps as big source of black carbon 2UC Davis researchers aid effort to sequence the complex wheat genome 2Double duty: Immune system regulator found to protect brain from effects of stroke 2